Bingyi Yao

发表

Characterization of a Novel CYP1A2 Knockout Rat Model Constructed by CRISPR/Cas9

Jian Lu, Jie Liu, Yuanqing Guo, 2021, Drug Metabolism and Disposition.

Cytochrome P450 2E1 gene knockout or inhibition prevents obesity induced by high-fat diet via regulating energy consumption in rats.

Peili Wang, Yuanjin Zhang, Xin Wang, 2022, Biochemical pharmacology.

The role of CYP1A1/2 in cholesterol ester accumulation provides a new perspective for the treatment of hypercholesterolemia

Ming-Yu Liu, Tieliu Shi, Jian Lu, 2022, Acta pharmaceutica Sinica. B.

Emerging role of carboxylesterases in nonalcoholic fatty liver disease.

Jie Liu, Yuanjin Zhang, Liangcai Gao, 2022, Biochemical pharmacology.

Investigation of cytochrome P450 inhibitory properties of deoxyshikonin, a bioactive compound from Lithospermum erythrorhizon Sieb. et Zucc.

Zhenliang Sun, Jie Liu, Yuanjin Zhang, 2022, Phytotherapy research : PTR.

Role of epoxyeicosatrienoic acids in cardiovascular diseases and cardiotoxicity of drugs.

Jie Liu, Yuanjin Zhang, Xin Wang, 2022, Life sciences.

3D organoids derived from the small intestine: An emerging tool for drug transport research

Yuanjin Zhang, Xin Wang, Sheng Huang, 2020, Acta pharmaceutica Sinica. B.

P-glycoprotein mediates the pharmacokinetic interaction of olanzapine with fluoxetine in rats.

Jian Lu, Jie Liu, Yuanqing Guo, 2021, Toxicology and applied pharmacology.

Establishment of LC–MS/MS method for quantifying chlorpromazine metabolites with application to its metabolism in liver and placenta microsomes

Yuanqing Guo, Yuanjin Zhang, Xin Wang, 2023, Journal of Pharmaceutical and Biomedical Analysis.

CYP2J deficiency leads to cardiac injury and presents dual regulatory effects on cardiac function in rats.

Jian Lu, Jie Liu, Yuanjin Zhang, 2023, Toxicology and applied pharmacology.

Construction and characterization of a humanized SLCO1B1 rat model with its application in evaluating the uptake of different statins

Jie Liu, Yuanqing Guo, Yuanjin Zhang, 2024, Acta pharmaceutica Sinica. B.

Non-alcoholic fatty liver disease changes the expression and activity of hepatic drug-metabolizing enzymes and transporters in rats.

Jie Liu, Yuanjin Zhang, Sheng Huang, 2024, Toxicology letters.

Sorafenib reduces the production of epoxyeicosatrienoic acids and leads to cardiac injury by inhibiting CYP2J in rats.

Jie Liu, Yuanqing Guo, Yuanjin Zhang, 2024, Biochemical pharmacology.